Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

282.15DKK
19 Oct 2018
Change (% chg)

kr.-1.10 (-0.39%)
Prev Close
kr.283.25
Open
kr.281.90
Day's High
kr.283.50
Day's Low
kr.279.80
Volume
2,313,831
Avg. Vol
2,348,823
52-wk High
kr.354.80
52-wk Low
kr.265.15

Latest Key Developments (Source: Significant Developments)

Novo Nordisk To Establish California Manufacturing Site For Stem Cell-Based Therapies
Monday, 1 Oct 2018 

Oct 1 (Reuters) - NOVO NORDISK A/S SAYS::WILL ESTABLISH CALIFORNIA MANUFACTURING SITE FOR STEM CELL-BASED THERAPIES.ANNOUNCED THE ESTABLISHMENT OF A MANUFACTURING SITE IN FREMONT, CALIFORNIA, US TO DEVELOP AND PRODUCE STEM CELL-BASED THERAPIES."OUR AMBITION IS TO DEVELOP STEM CELL-BASED THERAPIES FOR A RANGE OF SERIOUS CHRONIC DISEASES WHERE WE SEE SIGNIFICANT UNMET MEDICAL NEED," SAYS JACOB STEN PETERSEN, CORPORATE VICE PRESIDENT AND HEAD OF STEM CELL RESEARCH & DEVELOPMENT (R&D), NOVO NORDISK. ."THE RELIABLE, LARGE-SCALE SUPPLY OF THERAPIES IS A VITAL COMPONENT IN OUR EFFORTS, SO I AM DELIGHTED THAT WE HAVE ESTABLISHED THIS FACILITY THAT FURTHER DEMONSTRATES OUR STRONG COMMITMENT TO THIS FIELD.".ONCE OPERATIONAL IN 2019, FACILITY WILL FULFIL SUPPLY OF STEM CELL-BASED THERAPIES FOR NOVO NORDISK'S CLINICAL TRIAL PROGRAMMES.HAS SECURED A TWO-YEAR NON-EXCLUSIVE LICENCE ON ASTERIAS' INTELLECTUAL PROPERTY RELATING TO STEM CELL MANUFACTURING TECHNOLOGY.  Full Article

Novo Nordisk Says New Phase 2 Data For Somapacitan Demonstrate Its Potential
Friday, 28 Sep 2018 

Sept 28 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S - NEW PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE ITS POTENTIAL AS AN EFFICACIOUS ONCE-WEEKLY TREATMENT FOR CHILDHOOD GROWTH HORMONE DEFICIENCY.  Full Article

Novo Nordisk Canada Says Quebec To Provide Public Funding Of Tresiba
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK CANADA - QUEBEC GOVERNMENT TO PROVIDE PUBLIC FUNDING OF TRESIBA, AN INSULIN FOR TREATING ADULTS LIVING WITH TYPE 1 AND TYPE 2 DIABETES.  Full Article

Danish Govt, Novo Nordisk to partner with UN-anchored initiative on non-communicable diseases
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Novo Nordisk A/S ::DANISH GOVERNMENT, NOVO NORDISK ANNOUNCING GRANTS OF 3 AND 5 MILLION US DOLLARS RESPECTIVELY TO NEWLY ESTABLISHED DEFEAT-NCD PARTNERSHIP DURING LAUNCH EVENT AT UNGA.  Full Article

Novo Nordisk Says Oral Semaglutide Shows Superior Weight Loss, HbA1c Reduction In Pioneer 5 Trial
Monday, 20 Aug 2018 

Aug 20 (Reuters) - NOVO NORDISK A/S SAYS::ORAL SEMAGLUTIDE PROVIDES SUPERIOR HBA1C AND WEIGHT REDUCTIONS VERSUS PLACEBO IN PEOPLE WITH TYPE 2 DIABETES AND RENAL IMPAIRMENT IN THE PIONEER 5 TRIAL.TRIAL ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA(1C) WITH ORAL SEMAGLUTIDE COMPARED TO PLACEBO AT WEEK 26.PEOPLE TREATED WITH ORAL SEMAGLUTIDE ACHIEVED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN BODY WEIGHT COMPARED TO PLACEBO AT WEEK 26.  Full Article

Novo Nordisk Initiated New Share Repurchase Programme Of Up To Dkk 2.4 Bln As Part Of 2018 Share Repurchase Programme
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK-AS PART OF UP TO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME,CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AMOUNT OF UP TO DKK 2.4 BILLION.  Full Article

Novo Nordisk Purchases B Shares Worth DKK 954 Mln From Novo Holdings Under 2018 Share Repurchase Programme
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 954 MILLION FROM NOVO HOLDINGS A/S UNDER 2018 SHARE REPURCHASE PROGRAMME.TRANSACTION PART OF CO'S 2018 SHARE REPURCHASE PROGRAMME OF UP TO TOTAL OF DKK 14 BILLION TO BE EXECUTED DURING 12-MONTH PERIOD STARTING 1 FEB.TRANSACTION IS IN LINE WITH ANNOUNCEMENT ON 8 AUGUST THAT NOVO HOLDINGS INTENDS TO MAINTAIN OWNERSHIP OF NOVO NORDISK'S SHARE CAPITAL AROUND 28%.  Full Article

Therachon Raises $60 Million Mezzanine Financing
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Therachon AG::THERACHON RAISES $60 MILLION MEZZANINE FINANCING TO ADVANCE LEAD PROGRAM IN ACHONDROPLASIA AND TO EXPAND RARE DISEASE PIPELINE.THERACHON AG SAYS FINANCING LED BY NOVO HOLDINGS, JOINED BY COWEN HEALTHCARE INVESTMENTS, PFIZER VENTURES, AMONG OTHERS.  Full Article

Vattenfall, Novozymes, Novo Nordisk Sign Power Purchase Agreement From Denmark's Largest Offshore Wind Park
Friday, 13 Jul 2018 

July 13 (Reuters) - VATTENFALL AB [RIC:RIC:VATN.UL]::VATTENFALL, NOVOZYMES AND NOVO NORDISK SIGN A LONG TERM POWER PURCHASE AGREEMENT FROM DENMARK'S LARGEST OFFSHORE WIND PARK, KRIEGERS FLAK.SAYS DEAL WILL COVER APPROXIMATELY A FIFTH OF FARM'S PRODUCTION.KRIEGERS FLAK IS SCHEDULED TO BE IN FULL OPERATION BY THE END OF 2021.THE DEAL ENTERS INTO FORCE FROM JANUARY 1 2020. BETWEEN THEN AND 2021 THE POWER WILL BE SOURCED FROM OTHER VATTENFALL WIND FARMS IN DENMARK.  Full Article

Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Novo Nordisk A/S ::ORAL SEMAGLUTIDE SHOWS STATISTICALLY SIGNIFICANTLY GREATER REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO VICTOZA AND SITAGLIPTIN IN PIONEER 4 AND 7 TRIALS.PIONEER 4 ACHIEVED ITS PRIMARY OBJECTIVE ACCORDING TO PRIMARY STATISTICAL APPROACH BY DEMONSTRATING A NON-INFERIOR REDUCTION IN HBA1C.ORAL SEMAGLUTIDE PROVIDED STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA1C AND WEIGHT COMPARED TO PLACEBO..PLANS TO REPORT PIONEER 3 TRIAL COMPARING 3, 7 AND 14 MG ORAL SEMAGLUTIDE WITH 100 MG SITAGLIPTIN BEFORE END OF Q2 OF 2018.  Full Article

Photo

Beset by copies, Roche gets sales boost from China

ZURICH Roche's third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries.